Aeterna Zentaris Inc., a specialty biopharmaceutical company engaged in
developing and commercializing novel treatments in oncology and
endocrinology, announced a strategic co-promotion services agreement
with ASCEND Therapeutics US, LLC, (ASCEND), a specialty pharmaceutical
company solely focused on women's healthcare.
Under the terms of the agreement, expected to start in the fourth quarter of 2014, Aeterna Zentaris will use its newly established commercial structure to market, in specific US territories, ASCEND's EstroGel a non-patch transdermal US Food & Drug Administration (FDA) approved and commercialized estrogen replacement therapy. For its part, ASCEND would market, in specific US territories, Macrilen, Aeterna Zentaris' product for use in the evaluation of adult growth-hormone deficiency (AGHD), for which a New Drug Application (NDA) is currently under review by the FDA, with a Prescription Drug User Fee Act (PDUFA) date of November 5, 2014. In consideration for these co-promotion services, each party will be entitled to receive, from the other party, commissions on net sales of each other's product.
Under the terms of the agreement, expected to start in the fourth quarter of 2014, Aeterna Zentaris will use its newly established commercial structure to market, in specific US territories, ASCEND's EstroGel a non-patch transdermal US Food & Drug Administration (FDA) approved and commercialized estrogen replacement therapy. For its part, ASCEND would market, in specific US territories, Macrilen, Aeterna Zentaris' product for use in the evaluation of adult growth-hormone deficiency (AGHD), for which a New Drug Application (NDA) is currently under review by the FDA, with a Prescription Drug User Fee Act (PDUFA) date of November 5, 2014. In consideration for these co-promotion services, each party will be entitled to receive, from the other party, commissions on net sales of each other's product.
No comments:
Post a Comment